Morgan Stanley has upgraded PTC Therapeutics (PTCT), while downgrading Immuneering (IMRX) and Amicus Therapeutics (FOLD).

Morgan Stanley kept Apple as its "Top Pick" for 2025 as the bank sees the tech giant's artificial intelligence (AI) product ...

Joby Aviation's strategic investments and cash reserves, despite recent stock price volatility, position the company for ...

The stock's fall snapped a two-day winning streak.

Sempra (NYSE:SRE) +1.5% in Friday's trading as Morgan Stanley upgrades to Overweight from Equal Weight with a $98 price ...

After back-to-back years of more than 20% returns for the S&P 500, what's in store for 2025? Most on Wall Street say more ...

Import prices edged up 0.1% last month after a downwardly revised 0.1% rise in October, the Labor Department's Bureau of ...

A business update was the main news powering Alaska Air(NYSE: ALK) stock to a double-digit gain over the past few trading ...

Broadcom's (AVGO) quarterly results may have topped estimates, but its guidance of up to $90B in revenue from custom AI chips ...

Shares of Broadcom popped more than 21% Friday, pushing the company’s market cap beyond $1 trillion for the first time.

Fintel reports that on December 13, 2024, Morgan Stanley downgraded their outlook for Immunocore Holdings plc - Depositary ...

Morgan Stanley analyst Erik Woodring notes that Apple (AAPL) has outperformed the S&P 500 by 10 points over the last month and shares are ...